Omalizumab, manufactured by Genentech, was first FDA approved in 2003 to treat adults and children 12 years of age and older with moderate to severe persistent allergic asthma which is not controlled by inhaled steroids . Since its U.S. approval, more than 200,000 patients older than 12 with allergic asthma have been treated . In September 2018, a new prefil...
This drug is an anti-IgE antibody indicated for:
Massachusetts General Hospital, Department of Medicine: Allergy & Clinical Immunology Unit, Boston, Massachusetts, United States
Emory University School of Medicine: Children's Healthcare of Atlanta Pediatrics, Atlanta, Georgia, United States
Johns Hopkins Children's Center: Department of Allergy & Immunology, Baltimore, Maryland, United States
University of California San Diego (UCSD), San Diego, California, United States
University of California Los Angeles (UCLA), Los Angeles, California, United States
Sean N. Parker Center for Allergy & Asthma Research at Stanford University, Palo Alto, California, United States
Jonathan Corren MD, Inc., Los Angeles, California, United States
Brigham and Womens Hospital, Boston, Massachusetts, United States
Vitae Research Center, Miami, Florida, United States
Novartis Investigative Site, Toshima-Ku, Tokyo, Japan
Novartis Investigative Site, Shanghai, China
Northwell Health, Great Neck, New York, United States
CHAUQ Hospital St Sacrement, Quebec, Canada
Ottawa Allergy Research Corp, Ottawa, Ontario, Canada
Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain
UZ Gent, Gent, Belgium
Synexus - Warsaw, Warszawa, Poland
Sean N. Parker Center for Allergy and Asthma Research at Stanford, Mountain View, California, United States
UCLA, Los Angeles, California, United States
Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland, United States
University Clinic of Pulmonary and Allergic Diseases Golnik, Golnik, Slovenia
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.